The partnership with Confo Therapeutics will allow AbCellera to expand its product pipeline by discovering therapeutic antibody candidates targeting GPCR targets. This collaboration could lead to potential revenue growth through upfront payments, milestones, and tiered royalties on net product sales, positively impacting AbCellera's stock price in the short term.